Pirtobrutinib efficacy in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: Additional patients and extended follow-up from BRUIN

被引：0

作者：

Munir, Talha ^{[1
]}

Mato, Anthony R. ^{[2
]}

Woyach, Jennifer A. ^{[3
]}

Brown, Jennifer R. ^{[4
,5
]}

Ghia, Paolo ^{[6
,7
]}

Patel, Krish ^{[8
]}

Eyre, Toby A. ^{[9
]}

Lech-Maranda, Ewa ^{[10
]}

Lamanna, Nicole ^{[11
]}

Tam, Constantine S. ^{[12
,13
]}

Seymour, John F. ^{[12
,13
]}

Shah, Nirav N. ^{[14
]}

Coombs, Catherine C. ^{[15
]}

Ujjani, Chaitra S. ^{[16
]}

Patel, Manish R. ^{[17
]}

Fakhri, Bita ^{[18
]}

Cheah, Chan Y. ^{[19
,20
]}

Alencar, Alvaro J. ^{[21
]}

Cohen, Jonathon B. ^{[22
]}

Gerson, James N. ^{[23
]}

Flinn, Ian W. ^{[24
]}

Ma, Shuo ^{[25
]}

Jagadeesh, Deepa ^{[26
]}

Rhodes, Joanna M. ^{[27
]}

Hernandez-Ilizaliturri, Francisco ^{[28
]}

Zinzani, Pier Luigi ^{[29
]}

Balbas, Minna ^{[30
]}

Nair, Binoj ^{[30
]}

Abada, Paolo ^{[30
]}

Wang, Chunxiao ^{[31
]}

Wang, Denise ^{[30
]}

Tsai, Donald E. ^{[30
]}

Wierda, William G. ^{[32
]}

Jurczak, Wojciech ^{[33
]}

机构：

[1] St James Hosp, Leeds, W Yorkshire, England

[2] Mem Sloan Kettering Canc Ctr, New York, NY USA

[3] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA

[4] Dana Farber Canc Inst, Boston, MA USA

[5] Harvard Med Sch, Boston, MA USA

[6] Univ Vita Salute San Raffaele, Milan, Italy

[7] IRCCS Osped San Raffaele, Milan, Italy

[8] Swedish Canc Inst, Ctr Blood Disorders & Cellular Therapy, Seattle, WA USA

[9] Oxford Univ Hosp NHS Fdn Trust, Churchill Canc Ctr, Oxford, England

[10] Inst Hematol & Transfus Med, Warsaw, Poland

[11] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA

[12] Peter MacCallum Canc Ctr, Melbourne, Australia

[13] Univ Melbourne, Melbourne, Australia

[14] Med Coll Wisconsin, Milwaukee, WI USA

[15] Univ North Carolina Chapel Hill, Chapel Hill, NC USA

[16] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA

[17] Florida Canc Specialists Sarah Cannon Res Inst, Sarasota, FL USA

[18] Univ Calif San Francisco, San Francisco, CA USA

[19] Linear Clin Res, Perth, Australia

[20] Sir Charles Gairdner Hosp, Perth, Australia

[21] Univ Miami, Miller Sch Med, Miami, FL USA

[22] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[23] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA USA

[24] Sarah Cannon Res Inst, Nashville, TN USA

[25] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL USA

[26] Cleveland Clin, Cleveland, OH USA

[27] Northwell Hlth, Northwell Hlth Canc Inst, Donald & Barbara Zucker Sch Med Hofstra, New Hyde Pk, NY USA

[28] Roswell Pk Comprehens Canc Ctr, Lymphoma Sect, Dept Med Oncol, Buffalo, NY USA

[29] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[30] Loxo Lilly, Indianapolis, IN USA

[31] Eli Lilly & Co, Indianapolis, IN USA

[32] MD Anderson Canc Ctr, Houston, TX USA

[33] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH23-PO84

引用

页码：110 / 111

页数：2

共 50 条

[41] Efficacy and Safety of Parsaclisib in Patients With Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated With a BTK Inhibitor: Primary Analysis From a Phase 2 Study (CITADEL-205)
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 11 - 13
[42] Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.
Barr, Paul M.
Munir, Talha
Brown, Jennifer R.
O'Brien, Susan Mary
Barrientos, Jacqueline Claudia
Reddy, Nishitha M.
Coutre, Steven
Tam, Constantine Si Lun
Mulligan, Stephen P.
Jager, Ulrich
Kipps, Thomas J.
Moreno, Carol
Montillo, Marco
Burger, Jan Andreas
Byrd, John C.
Hillmen, Peter
Dai, Sandra
Szoke, Anita
Dean, James P.
Woyach, Jennifer Ann
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[43] Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (01)
[44] Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)
Brown, Jennifer R.
Eichhorst, Barbara F.
Lamanna, Nicole
O'Brien, Susan M.
Tam, Constantine S.
Qiu, Luqui
Kazmierczak, Maciej
Jurczak, Wojciech
Zhou, Keshu
Simkovic, Martin
Mayer, Jiri
Gillespie-Twardy, Amanda L.
Ferrajoli, Alessandra
Ganly, Peter S.
Weinkove, Robert
Grosicki, Sebastian
Mital, Andrzej
Robak, Tadeusz
Osterborg, Anders
Yimer, Habte A.
Wang, Megan
Salmi, Tommi
Wang, Liping
Li, Jessica
Wu, Kenneth
Cohen, Aileen Cleary
Shadman, Mazyar
BLOOD, 2023, 142
[45] Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
Burger, Jan A.
Barr, Paul M.
Robak, Tadeusz
Owen, Carolyn
Ghia, Paolo
Tedeschi, Alessandra
Bairey, Osnat
Hillmen, Peter
Coutre, Steven E.
Devereux, Stephen
Grosicki, Sebastian
McCarthy, Helen
Simpson, David
Offner, Fritz
Moreno, Carol
Dai, Sandra
Lal, Indu
Dean, James P.
Kipps, Thomas J.
LEUKEMIA, 2020, 34 (03) : 787 - 798
[46] Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
Jan A. Burger
Paul M. Barr
Tadeusz Robak
Carolyn Owen
Paolo Ghia
Alessandra Tedeschi
Osnat Bairey
Peter Hillmen
Steven E. Coutre
Stephen Devereux
Sebastian Grosicki
Helen McCarthy
David Simpson
Fritz Offner
Carol Moreno
Sandra Dai
Indu Lal
James P. Dean
Thomas J. Kipps
Leukemia, 2020, 34 : 787 - 798
[47] A Phase (Ph) 2 Study of TL-895, a Highly Selective, Novel Covalent BTK Inhibitor (BTKi), in Patients (pts) with Treatment-Naive (TN) and Relapsed/Refractory (R/R) BTKi-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Byrd, John C.
Woszczyk, Dariusz
Illes, Arpad
Jurczak, Wojciech
Chraniuk, Dominik
Giannopoulos, Krzysztof
Mikhailova, Nataliia
Illconzai, Peter
Bhat, Seema A.
Romanyuk, Nataliya
Usenko, Ganna
Kuchkova, Olha
Chandler, Jason
Bilotti, Elizabeth
Shen, Annalise
Cheung, Jean
Verstovsek, Srdan
McGreivy, Jesse
Rothbaum, Wayne
Kazmierczak, Maciej
BLOOD, 2023, 142
[48] Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients
Siddiqi, Tanya
Soumerai, Jacob D.
Dorritie, Kathleen A.
Stephens, Deborah M.
Riedell, Peter A.
Arnason, Jon E.
Kipps, Thomas J.
Gillenwater, Heidi H.
Gong, Lucy
Yang, Lin
Ogasawara, Ken
Wierda, William G.
BLOOD, 2020, 136
[49] Final Results and Follow-up of a Phase I Study of the Fc Engineered CD19 Antibody XmAb®5574 (aka MOR00208) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Woyach, Jennifer A.
Awan, Farrukh
Flinn, Ian
Berdeja, Jesus G.
Wiley, Elizabeth A.
Mansoor, Sharmeen
Huang, Ying
Lozanski, Gerard
Foster, Paul A.
Byrd, John C.
BLOOD, 2014, 124 (21)
[50] Efficacy controls and long-term follow-up of patients (pts) treated with rituximab for relapsed or refractory, low-grade or follicular (R-LG/F) NHL.
McLaughlin, P
Grillo-López, AJ
Maloney, DG
Link, BK
Levy, R
Czuczman, MS
Cabanillas, F
Dallaire, BK
White, CA
BLOOD, 1998, 92 (10) : 414A - 415A

← 1 2 3 4 5 →